NasdaqGM - Nasdaq Real Time Price USD

Sutro Biopharma, Inc. (STRO)

Compare
1.7200
-0.0700
(-3.91%)
At close: 4:00:01 PM EST
1.7182
-0.00
(-0.10%)
After hours: 5:52:01 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
160,955.0000
153,731.0000
67,772.0000
61,880.0000
42,722.0000
Operating Expense
290,998.0000
243,009.0000
196,715.0000
160,404.0000
113,779.0000
Operating Income
-130,043.0000
-89,278.0000
-128,943.0000
-98,524.0000
-71,057.0000
Net Non Operating Interest Income Expense
14,011.0000
-9,240.0000
109.0000
-2,560.0000
-2,466.0000
Other Income Expense
--
9,917.0000
12,130.0000
-4,454.0000
41,498.0000
Pretax Income
-108,138.0000
-88,601.0000
-116,704.0000
-105,538.0000
-32,025.0000
Tax Provision
15,815.0000
18,192.0000
2,500.0000
--
103.0000
Net Income Common Stockholders
-123,953.0000
-106,793.0000
-119,204.0000
-105,538.0000
-32,128.0000
Diluted NI Available to Com Stockholders
-123,953.0000
-106,793.0000
-119,204.0000
-105,538.0000
-32,128.0000
Basic EPS
-1.55
-1.78
-2.35
-2.29
-0.99
Diluted EPS
-1.55
-1.78
-2.35
-2.29
-0.99
Basic Average Shares
71,443.9590
60,163.5420
50,739.1850
46,119.0890
32,573.4690
Diluted Average Shares
71,443.9590
60,163.5420
50,739.1850
46,119.0890
32,573.4690
Total Operating Income as Reported
-130,043.0000
-89,278.0000
-128,943.0000
-98,524.0000
-71,057.0000
Total Expenses
290,998.0000
243,009.0000
196,715.0000
160,404.0000
113,779.0000
Net Income from Continuing & Discontinued Operation
-123,953.0000
-106,793.0000
-119,204.0000
-105,538.0000
-32,128.0000
Normalized Income
-130,189.2600
-114,627.4300
-128,786.7000
-101,084.0000
-62,421.5400
Interest Income
45,123.0000
14,510.0000
3,455.0000
577.0000
1,508.0000
Interest Expense
31,112.0000
23,750.0000
3,346.0000
3,137.0000
3,974.0000
Net Interest Income
14,011.0000
-9,240.0000
109.0000
-2,560.0000
-2,466.0000
EBIT
-77,026.0000
-64,851.0000
-113,358.0000
-102,401.0000
-28,051.0000
EBITDA
-69,945.0000
-58,035.0000
-107,668.0000
-97,557.0000
-23,754.0000
Reconciled Depreciation
7,081.0000
6,816.0000
5,690.0000
4,844.0000
4,297.0000
Net Income from Continuing Operation Net Minority Interest
-123,953.0000
-106,793.0000
-119,204.0000
-105,538.0000
-32,128.0000
Total Unusual Items Excluding Goodwill
7,894.0000
9,917.0000
12,130.0000
-4,454.0000
41,498.0000
Total Unusual Items
7,894.0000
9,917.0000
12,130.0000
-4,454.0000
41,498.0000
Normalized EBITDA
-77,839.0000
-67,952.0000
-119,798.0000
-93,103.0000
-65,252.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
--
0.0003
Tax Effect of Unusual Items
1,657.7400
2,082.5700
2,547.3000
--
11,204.4600
12/31/2020 - 9/27/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

STOK Stoke Therapeutics, Inc.
8.68
-2.69%
 
CTMX CytomX Therapeutics, Inc.
0.8410
-5.23%
 
MRSN Mersana Therapeutics, Inc.
0.6340
+2.01%
 
ZNTL Zentalis Pharmaceuticals, Inc.
2.6450
+3.32%
 
YMAB Y-mAbs Therapeutics, Inc.
6.33
-2.62%
 
REPL Replimune Group, Inc.
10.49
-3.67%
 
INZY Inozyme Pharma, Inc.
1.5100
-12.21%
 
NUVB Nuvation Bio Inc.
2.5900
-3.00%
 
CLSD Clearside Biomedical, Inc.
0.9200
-1.03%
 
ADCT ADC Therapeutics SA
1.7100
-0.58%